The Food and Drug Administration yesterday updated its fact sheets for providers and recipients and caregivers for the Johnson & Johnson COVID-19 vaccine, with each revised document outlining a contraindication for the vaccine’s administration to individuals with histories of thrombosis with thrombocytopenia following doses of this or any other adenovirus-vectored COVID-19 vaccine. The updated fact sheets discuss the risk of thrombosis with thrombocytopenia syndrome following vaccination, an ailment that has been observed in males and females 18 years of age and older, with females 30-49 years of age experiencing the highest reporting rate (approximately one case per 100,000 administered doses). Overall, thrombosis with thrombocytopenia syndrome is fatal in approximately one out of seven cases.

Related News Articles

Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…